VIVUS INITIATES PREMATURE EJACULATION CLINICAL TRIAL.
VIVUS, Inc. (Nasdaq NM: VVUS), Mountain View, Calif., has initiated
a clinical trial to evaluate the safety and efficacy of VI-0162, its
proprietary, oral, on-demand treatment for premature . . .
ANTEX GETS FIVE NEW INTERNATIONAL PATENTS.
Antex Biologics Inc. (Amex: ANX), Gaithersburg, Md., has been
issued five new patents, increasing the company's total patent
portfolio to 116 issued patents. The company also has over 300 . . .
PRE-HOSPITAL THROMBOLYTIC HEART ATTACK TREATMENT
FEASIBLE.
Genentech (NYSE:DNA) has announced that results from the ASSENT 3
PLUS trial demonstrate pre-hospital administration of the single-bolus
thrombolytic (clot-dissolving) agent TNKase(TM) . . .
IVAX TO DEVELOP/MARKET LMB-9 IMMUNOTOXIN CANCER
TREATMENT.
IVAX Corporation (AMEX:IVX) (LSE:IVX.L), Miami, Fla., has assumed
worldwide rights to develop and market LMB-9, a recombinant immunotoxin
which was designed as a treatment for a wide variety of . . .
AVI BIOPHARMA'S NEUGENE PROVED SAFE IN ADULT PKD
PATIENTS.
AVI BioPharma, Inc. (Nasdaq:AVII)(Nasdaq:AVIIW)(Nasdaq:AVIIZ),
Portland, Ore, has announced that its NEUGENE(R) antisense drug
(AVI-4126) has proved safe in adult patients with autosomal . . .
PURE PROTEIN L.L.C. DEBUTS POLYTEST BINDING ASSAY.
Emergent Technologies Inc. (ETI), has announced that its portfolio
company, Pure Protein L.L.C., has commercialized an accurate and
sensitive assay for peptides binding to HLA molecules based on . . .
NYMOX GETS U.S. PATENT FOR STATIN FOR ALZHEIMER'S
DISEASE.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX), Maywood, N.J., has
been issued a U.S. patent for the use of statin drugs for the treatment
and prevention of Alzheimer's disease.
Statins are a . . .
FDA APPROVES MARKETING OF TESTIM TESTOSTERONE REPLACEMENT
GEL.
Bentley Pharmaceuticals, Inc. (AMEX: BNT), North Hampton, N.H.,a
specialty pharmaceutical company focused on advanced drug-delivery
technologies, which also manufactures and markets generic and . . .
US BIOSERVICES ACQUIRES DOCUMEDICS.
US Bioservices Corporation, a specialty pharmaceutical distribution
and services company based in Washington, D.C., has acquired Documedics,
a San Bruno, Calif.-based pharmaceutical services . . .
CARDINAL HEALTH TO FORMULATE NEW HEART DRUG.
Endovasc Ltd. Inc. (OTC Bulletin Board:ENVC), Montgomery, Texas, a
biotechnology company with two potential blockbuster cardiovascular
drugs approved for final FDA Phase III human trials has signed . . .
ZENGEN FILES IND NEW FOR VAGINAL YEAST INFECTION
TREATMENT.
Zengen, Inc., Woodland Hills, Calif., has filed an Investigational
New Drug (IND) application with the U.S. Food and Drug Administration
for CZEN 002, one of the company's proprietary peptide . . .
PALATIN'S MALE ERECTILE DYSFUNCTION TREATMENT
EFFICACIOUS.
Both Palatin Technologies Inc. (AMEX:PTN) and Jacob Rajfer, MD,
Professor of Urology at UCLA School of Medicine, presented results of
the Phase 2A clinical trial of PT-141, the company's . . .
NEBULIZED ANTIBIOTIC THERAPY PROMISING FOR CHRONIC
SINUSITIS.
In the peer-reviewed journal ENT (Ear, Nose & Throat), a new
published research study by Dr. Philip Scheinberg finds that nebulized
antibiotic therapy from SinusPharmacy Corporation is an effective . . .
TULARIK BEGINS PHASE 1 CLINICAL TRIAL OF
ANTI-INFLAMMATORY.
Tularik Inc. (Nasdaq:TLRK), South San Francisco, has initiated a
Phase 1 clinical trial to evaluate the safety and pharmacokinetic
profile of T487, an orally active small molecule agent that . . .
US BIOSERVICES ACQUIRES PHARM PLUS RESOURCES, INC.
US Bioservices Corporation, a specialty pharmaceutical distribution
and services company based in Washington, D.C., has acquired Pharm Plus
Resources, Inc., a pharmaceutical distribution company . . .
ENDOVASC SPINS OFF ANTI-INFLAMATORY/CARDIOVASCULAR DRUG.
Endovasc Ltd., Inc. (OTCBB:ENVC), Montgomery, Texas, has announced
that in accordance with its new business model, the company has
established a new subsidiary, Liprostin(TM) Development . . .
CYPRESS PROGRAM TO EVALUATE EFFICACY OF MILNACIPRAN.
Cypress Bioscience Inc. (Nasdaq:CYPB), San Diego, has announced
that, as part of its commitment to be the innovator and commercial
leader in providing products for the diagnosis and treatment of . . .
JOINT GENOME INSTITUTE TO SEQUENCE AFRICAN FROG GENOME
DNA.
In their continuing search for new clues to how human genes
function and how vertebrates develop and evolve, researchers at the U.S.
Department of Energy's Joint Genome Institute (JGI) are gearing . . .
JOHNS HOPKINS/CORRELOGIC TO DEVELOP COMPUTER DIAGNOSTIC
MODELS.
Johns Hopkins University and Correlogic Systems, Inc. have entered
into a collaborative research agreement to develop computational
diagnostic models of inflammatory vascular diseases. . . .
VIACELL LICENSES PROTEIN FOR STROKE RECOVERY TREATMENT.
ViaCell Inc., Boston, a premier cellular therapy company, has
obtained an exclusive worldwide license for dimerized fibroblast growth
factor (dFGF), a novel protein developed by scientists at . . .
|
|